跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD20 CAR-T
首页
药物
CD20 CAR-T
CD20 CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20
EP 3240805 B1
申请人: UNIV CALIFORNIA
优先权: 2014
EP
US
WO
19 件公开
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US 11207349 B2
申请人: CELLULAR BIOMEDICINE GROUP HK LTD
优先权: 2020
CN
EP
US
WO
16 件公开
CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
EP 3523331 A1
申请人: NOVARTIS AG
优先权: 2016
CN
EP
US
WO
15 件公开
CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL
EP 3280729 B1
申请人: NOVARTIS AG
优先权: 2015
CN
EP
US
WO
14 件公开
CHIMERIC ANTIGEN RECEPTORS AND CAR-T CELLS AND METHODS OF USE
EP 3893899 A2
申请人: KITE PHARMA INC
优先权: 2018
CN
EP
US
WO
14 件公开
ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES
EP 4323403 A1
申请人: TENEOBIO INC
优先权: 2021
CN
EP
US
WO
7 件公开
COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED GAMMA-DELTA T CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
EP 3860645 A1
申请人: ADICET BIO INC
优先权: 2018
CN
EP
US
WO
5 件公开
CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES
EP 4259650 A1
申请人: OSPEDALE PEDIATRICO BAMBINO GESÙ
优先权: 2020
CN
EP
US
WO
5 件公开
IMMUNE EFFECTOR CELL AND USE THEREOF
EP 4714981 A1
申请人: CARSGEN LIFE SCIENCES CO LTD
优先权: 2023
CN
EP
WO
4 件公开
TREATMENT OF B CELL MALIGNANCIES
US 20250025504 A1
申请人: ADICET THERAPEUTICS INC
优先权: 2021
CN
US
2 件公开
第 1 / 6 页
上一页
下一页
药物
反馈